Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
Yahoo21 gün önceALT
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Yahoo22 gün önceALT
Altimmune: Pemvidutide Performs, But A Long Wait Ahead
SeekingAlpha22 gün önceALT
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...
Altimmune reports positive Phase 2 AUD data and rapid progress in its MASH Phase 3 trial, backed by $519 million in cash.
Yahoo22 gün önceALT
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
SeekingAlpha23 gün önceALT
Altimmune Q2 Earnings Call Highlights
Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD. Chairman and Chief Executive Office
Yahoo23 gün önceALT
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Yahoo23 gün önceALT